Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax
Latest Information Update: 13 Sep 2024
At a glance
- Drugs Venetoclax (Primary) ; Cytarabine; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms RELAX
Most Recent Events
- 12 Dec 2023 updated results from the phase-I and additional patients from the phase-II dose expansion in relapsed or refractory (r/r) AML patients, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 13 Sep 2023 Planned End Date changed from 1 Apr 2025 to 1 Aug 2025.
- 13 Sep 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Oct 2023.